AbbVie Q3 Income Advances

What happened

AbbVie reported third-quarter profit of $4.218 billion, or $2.37 per share, up from $186 million, or $0.10 per share, a year earlier. Revenue rose 10.3% to $17.404 billion from $15.776 billion. Adjusted earnings were $6.795 billion, or $3.82 per share, and full-year earnings guidance is $13.95 to $13.99 per share.

Confirmed

Global impact / market context

Much higher profit and 10.3% revenue growth show AbbVie sold more and kept more profit per sale, which means more cash available for research, debt repayment, or shareholder returns. The wide gap between reported and adjusted earnings means investors should check one-time items behind the numbers.

Analyst inference

Investors compare this result with last year's weak quarter and with the full-year guidance of $13.95 to $13.99 per share. That guidance range, a company forecast rather than a confirmed result, helps investors judge whether profit growth can continue and how the stock is priced.

Analyst inference

What to watch

1. AbbVie's full-year earnings guidance is $13.95 to $13.99 per share, which means management expects continued profit. Watch whether later results stay inside this range, because falling short could hurt investor confidence. Confirmed
2. Company guidance suggests management expects profit to hold near current levels, so watch whether revenue keeps growing at a similar pace and whether the gap between reported and adjusted earnings narrows. Proposed
3. If revenue growth continues, AbbVie should generate more cash available for capital spending, which means money for research and facilities, and for shareholder returns. Slower growth could reverse that support for the stock. Analyst inference

Evidence

• Original source link unavailable